Mylan's generic arthritis drug receives FDA approval

PITTSBURGH The Food and Drug Administration has approved a generic arthritis treatment made by Mylan, the drug maker said Wednesday.

The FDA approved nabumetone tablets, a treatment for osteoarthritis and rheumatoid arthritis, in the 500 mg and 750-mg strengths.

Nabumetone tablets had sales of $68 million during the 12-month period ended in March, according to IMS Health. SmithKline Beecham, a predecessor company to GlaxoSmithKline, originally sold nabumetone tablets under the brand name Relafen, though Relafen no longer is available.